Who are BH009 (Docetaxel injection)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Docetaxel (DOC), Docetaxel (D), ZENTEL and Vitamin A Soft Capsules, ''albendazole'' and ''ivermectin'', Cabazitaxel (XRP6258), Paclitaxel injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bh009-docetaxel-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BH009 (Docetaxel injection) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BH009 (Docetaxel injection) (BH009 (Docetaxel injection)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BH009 (Docetaxel injection) (BH009 (Docetaxel injection)) — Zhuhai Beihai Biotech Co., Ltd. Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BH009 (Docetaxel injection) TARGET	BH009 (Docetaxel injection)	Zhuhai Beihai Biotech Co., Ltd	phase 3	Taxane; microtubule stabilizer	β-tubulin
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
ZENTEL and Vitamin A Soft Capsules	ZENTEL and Vitamin A Soft Capsules	Chengdu Maternal and Children's Health Care Hospital	marketed	Anthelmintic + Vitamin supplement	β-tubulin (albendazole component)
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

Sanofi · 2 drugs in this class
Aravive, Inc. · 1 drug in this class
Athenex, Inc. · 1 drug in this class
Barts & The London NHS Trust · 1 drug in this class
BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Dai, Guanghai · 1 drug in this class
Fujian Medical University · 1 drug in this class
Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BH009 (Docetaxel injection) — Competitive Intelligence Brief. https://druglandscape.com/ci/bh009-docetaxel-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing